Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Non Operating Income: 2012-2024

Historic Non Operating Income for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $3.4 million.

  • Coherus Oncology's Non Operating Income rose 2.74% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 65.32%. This contributed to the annual value of $3.4 million for FY2024, which is 38.33% down from last year.
  • Coherus Oncology's Non Operating Income amounted to $3.4 million in FY2024, which was down 38.33% from $5.5 million recorded in FY2023.
  • In the past 5 years, Coherus Oncology's Non Operating Income ranged from a high of $5.5 million in FY2023 and a low of -$283,000 during FY2021.
  • Over the past 3 years, Coherus Oncology's median Non Operating Income value was $3.8 million (recorded in 2022), while the average stood at $4.2 million.
  • Per our database at Business Quant, Coherus Oncology's Non Operating Income slumped by 151.08% in 2021 and then soared by 1,450.53% in 2022.
  • Over the past 5 years, Coherus Oncology's Non Operating Income (Yearly) stood at $554,000 in 2020, then crashed by 151.08% to -$283,000 in 2021, then spiked by 1,450.53% to $3.8 million in 2022, then skyrocketed by 43.09% to $5.5 million in 2023, then tumbled by 38.33% to $3.4 million in 2024.